Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma
Crossref DOI link: https://doi.org/10.1007/s00277-020-04285-y
Published Online: 2020-10-01
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moore, Donald C.
Nelson, Viera
Muslimani, Alaa
Text and Data Mining valid from 2020-10-01
Version of Record valid from 2020-10-01
Article History
Received: 15 July 2020
Accepted: 23 September 2020
First Online: 1 October 2020